FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a pharmaceutical composition comprising a medicinal agent and a polypeptide represented by Ac-(Arg-Ala-Asp-Ala)4-NH2, and further comprising an organic solvent, selected from a group consisting of polyethylene glycol, dimethylsulphoxide, glycofurol and N-methylpyrrolidone. Prolonged release of the drug in the body.
EFFECT: disclosed is a pharmaceutical composition comprising a polypeptide.
15 cl, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DEPOT FORM OF SOMATOSTATIN ANALOGUE AND METHOD FOR MAKING THEREOF | 2005 |
|
RU2411031C2 |
| DOSAGE MODE OF PTH COMPOUND OF CONTROLLED RELEASE | 2017 |
|
RU2777357C2 |
| PTH COMPOUNDS WITH LOW PEAK-TO-MINIMUM RATIOS | 2017 |
|
RU2766959C2 |
| CNP PRODRUGS | 2016 |
|
RU2824988C1 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
| PHARMACEUTICAL COMPOSITIONS | 2014 |
|
RU2690377C2 |
| METASTIN DERIVATIVES AND USE THEREOF | 2007 |
|
RU2454425C2 |
| PEGILATED BIOLOGICALLY ACTIVE PEPTIDES AND THEIR APPLICATION | 2017 |
|
RU2748576C2 |
| SPECIFIC ACTIVATOR AKT3 AND ITS USE | 2018 |
|
RU2815372C2 |
| PHARMACEUTICAL COMPOSITION | 1994 |
|
RU2126264C1 |
